Online citations, reference lists, and bibliographies.

Current Patient Perspectives Of Vulvovaginal Candidiasis: Incidence, Symptoms, Management And Post-treatment Outcomes

J. Yano, J. Sobel, P. Nyirjesy, R. Sobel, Valerie S. L. Williams, Q. Yu, M. C. Noverr, P. Fidel
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BackgroundVulvovaginal candidiasis (VVC) is a common infection affecting women worldwide. Reports of patterns/risk factors/trends for episodic/recurrent VVC (RVVC) are largely outdated. The purpose of this study was to obtain current patient perspectives of several aspects of VVC/RVVC.MethodsBusiness cards containing on-line survey information were distributed to healthy volunteers and patients seeking standard, elective, or referral gynecologic care in university-affiliated Obstetrics/Gynecology clinics. The internet-based questionnaire was completed by 284 non-pregnant women (78% Caucasian, 14% African American, 8% Asian).ResultsThe majority of the participants (78%) indicated a history of VVC with 34% defined as having RVVC. The most common signs/symptoms experienced were itching, burning and redness with similar ranking of symptoms among VVC and RVVC patients. Among risk factors, antibiotic use ranked highest followed by intercourse, humid weather and use of feminine hygiene products. A high number of respondents noted ‘no known cause’ (idiopathic episodes) that was surprisingly similar among women with a history of either VVC or RVVC. VVC/RVVC episodes reported were primarily physician-diagnosed (73%) with the remainder mostly reporting self-diagnosis and treating with over-the-counter (OTC) medications. Most physician-diagnosed attacks utilized a combination of pelvic examination and laboratory tests followed by prescribed antifungals. Physician-treated cases achieved a higher level of symptom relief (84%) compared to those who self-medicated (57%). The majority of women with RVVC (71%) required continual or long-term antifungal medication as maintenance therapy to control symptoms.ConclusionsCurrent patient perspectives closely reflect historically documented estimates of VVC/RVVC prevalence and trends regarding symptomatology, disease management and post-treatment outcomes.
This paper references
10.1016/S1473-3099(18)30103-8
Global burden of recurrent vulvovaginal candidiasis: a systematic review.
D. Denning (2018)
10.1001/jama.1984.03340290034016
Establishing the cause of genitourinary symptoms in women in a family practice. Comparison of clinical examination and comprehensive microbiology.
A. Berg (1984)
10.1097/LGT.0b013e3182241f1a
Vulvovaginal Candidiasis in Postmenopausal Women: The Role of Hormone Replacement Therapy
G. Fischer (2011)
10.1186/1471-2334-2-1
Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes
Ella M de Leon (2002)
10.1097/00001648-199603000-00013
Risk Factors for Vulvovaginal Candidiasis: A Case- Control Study among University Students
A. Geiger (1996)
in the host response to Candida vaginitis : identifying a role for non - classical immune mediators , S 100 alarmins
J Yano (2012)
10.1097/LGT.0b013e318273e8cf
Prevalence of Recurrent Vulvovaginal Candidiasis in 5 European Countries and the United States: Results From an Internet Panel Survey
B. Foxman (2013)
10.1371/journal.pone.0054379
Characterization of the Vaginal Micro- and Mycobiome in Asymptomatic Reproductive-Age Estonian Women
Tiina Drell (2013)
10.1016/S0002-9378(98)80001-X
Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations.
J. Sobel (1998)
Candida vaginitis: selfreported incidence and associated costs
B Foxman (2000)
10.1067/MOB.2001.115116
Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole.
J. Sobel (2001)
10.1007/978-3-642-83312-0
Vulvovaginal Candidosis
Dr. Werner Mendling (1988)
10.1056/NEJMOA033114
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.
J. Sobel (2004)
10.1097/00007435-200004000-00009
Candida vaginitis: Self‐Reported Incidence and Associated Costs
B. Foxman (2000)
10.1128/CMR.00076-09
Candida Infections of the Genitourinary Tract
J. Achkar (2010)
10.4236/AID.2013.34035
Prevalence of Non- Albicans Candida Infections in Women with Recurrent Vulvovaginal Symptomatology
Jason D. Mintz (2013)
10.1136/pgmj.55.647.645
Candida vaginitis
R. Hurley (1979)
10.1128/IAI.72.5.2939-2946.2004
An Intravaginal Live Candida Challenge in Humans Leads to New Hypotheses for the Immunopathogenesis of Vulvovaginal Candidiasis
P. Fidel (2004)
10.1097/00006254-198710000-00019
Sexual Transmission of Candida
B. Horowitz (1987)
10.1016/j.cyto.2011.11.021
Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins.
J. Yano (2012)
10.1371/journal.ppat.1003965
Candida Vaginitis: When Opportunism Knocks, the Host Responds
B. M. Peters (2014)
10.1093/clinids/20.Supplement_1.S80
Treatment options for vulvovaginal candidiasis, 1993.
S. Reef (1995)
Risk factors for vulvovaginal candidiasis: a casecontrol study among university students. Epidemiology
AM Geiger (1996)
10.1089/JWH.1998.7.1167
Frequency and response to vaginal symptoms among white and African American women: results of a random digit dialing survey.
B. Foxman (1998)
10.1001/JAMA.291.11.1368
Evaluation of vaginal complaints.
M. Anderson (2004)
10.1016/j.annepidem.2017.08.010
Recurrent vulvovaginal candidiasis.
Freida A Blostein (2017)
Treatment options for vulvovaginal candidiasis
SE Reef (1993)
10.1093/clinids/14.Supplement_1.S148
Pathogenesis and treatment of recurrent vulvovaginal candidiasis.
J. Sobel (1992)
10.1136/sti.71.5.304
Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida.
A. Geiger (1995)
10.1128/mBio.00211-17
Vaginal Heparan Sulfate Linked to Neutrophil Dysfunction in the Acute Inflammatory Response Associated with Experimental Vulvovaginal Candidiasis
J. Yano (2017)
10.2105/AJPH.85.8_Pt_1.1146
The epidemiology of vulvovaginal candidiasis among university students.
A. Geiger (1995)
10.1016/S0002-9378(85)80003-X
Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis.
J. Sobel (1985)
You mention the clinical outcomes of VVC/RVVC: relief rate considerably lower in women with OTC treatment
Denning (2011)
10.1126/scitranslmed.3002613
Repeated Vulvovaginal Fungal Infections Cause Persistent Pain in a Mouse Model of Vulvodynia
Melissa A. Farmer (2011)
10.1016/J.TIM.2004.03.006
History and new insights into host defense against vaginal candidiasis.
P. Fidel (2004)
10.1111/1471-0528.12994
Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects
A. Cassone (2015)



This paper is referenced by
10.1007/s12281-019-00357-3
Update of Vulvovaginal Candidiasis in Pregnant and Non-pregnant Patients
Tito Ramírez-Lozada (2019)
10.3390/pathogens9060489
In Vitro Incorporation of Helicobacter pylori into Candida albicans Caused by Acidic pH Stress
Kimberly Sánchez-Alonzo (2020)
10.1186/s40779-019-0226-5
Correlation between exercise, personal income level and health-related quality of life in patients with newly diagnosed stable angina
Yi Wang (2019)
10.1007/s11908-020-0712-7
Fluconazole Prophylaxis in Prevention of Symptomatic Candida Vaginitis
Kannika Story (2020)
10.29252/SJKU.24.5.105
Effect of honey and yogurt on vaginal candidiasis: A systematic review and meta- analysis of clinical trials
Fatemeh Zahra Karimi (2019)
10.1016/j.carbpol.2019.115608
Amphotericin B-loaded Eudragit RL100 nanoparticles coated with hyaluronic acid for the treatment of vulvovaginal candidiasis.
Carolina Mirtes Melo (2020)
10.3390/microorganisms8010034
Curative Treatment of Candidiasis by the Live Biotherapeutic Microorganism Lactobacillus rhamnosus Lcr35® in the Invertebrate Model Caenorhabditis elegans: First Mechanistic Insights
Cyril Poupet (2019)
10.3390/jof6010035
Applying the Host-Microbe Damage Response Framework to Candida Pathogenesis: Current and Prospective Strategies to Reduce Damage
Paul L Fidel (2020)
10.1016/j.tim.2019.07.006
Host-Pathogen Interactions during Female Genital Tract Infections.
M. Pekmezovic (2019)
10.1016/J.BCAB.2019.101195
Anti-candidal and anti-virulence efficiency of selected seaweeds against azole resistance Candida albicans
Ganeshkumar Arumugam (2019)
10.1128/AAC.01777-19
Second-Generation Antidiabetic Sulfonylureas Inhibit Candida albicans and Candidalysin-Mediated Activation of the NLRP3 Inflammasome
David J. Lowes (2019)
10.1109/EMBC44109.2020.9176288
Detection of Filamentous Microorganisms in Fluorescence Microscopy Images
Yongjian Yu (2020)
10.2147/IDR.S226154
Antifungal Activity of ZnO Nanoparticles and Nystatin and Downregulation of SAP1-3 Genes Expression in Fluconazole-Resistant Candida albicans Isolates from Vulvovaginal Candidiasis
Seyededeh Sedigheh Hosseini (2020)
10.1007/s00404-020-05784-z
Vaginal tablets of dequalinium chloride 10 mg versus clotrimazole 100 mg for vaginal candidiasis: a double-blind, randomized study
Manopchai Thamkhantho (2020)
10.1093/cid/ciaa260
Diagnosis and Treatment of Vaginal Discharge Syndromes in Community Practice Settings.
S. Hillier (2020)
Semantic Scholar Logo Some data provided by SemanticScholar